“AstraZeneca has seen a surge in interest amongst investors following its vaccine breakthrough which not only showed better than expected efficacy rates, but the potential for worldwide distribution given the ease of storage compared to its rivals. GlaxoSmithKline is expected to report results of its vaccine trials it has collaborated on with Sanofi and given the triple success the markets have already digested, hopes are riding high that it will also come up with the goods, which is why its shares are also sought after.”